Stay updated with breaking news from Agonist. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The report 'Antibody conjugates for targeted delivery of Toll-like receptor 9 agonist to the tumor tissue', published in the PLOS ONE journal, highlights MHRA research which showed that genetic engineering of antibodies used to activate and support the immune system against cancer leads to improvements in their reliability and effectiveness.
— Presentation entitled BMB-101: A selective 5-HT2C agonist in clinical trials with therapeutic utility — — First-in-human Phase 1 trial for lead program, BMB-101,... | April 10, 2023
NASH Renaissance 2023 Pemvidutide-Potent GLP-1/Glucagon Dual Receptor Agonist for the Treatment of NASH and Obesity Evercore ISI Research... | March 30, 2023
Researchers provide evidence that a novel vaccine candidate robustly neutralized SARS-CoV-2 Omicron subvariants BQ.1.1 and XBB.
Patients with 'blinding' headaches known as Idiopathic Intercranial Hypertension could be treated with an injectable peptide used for type 2 diabetes, a new trial has found.